Advertisement
Screener

Generate Biomedicines, Inc. (GENB) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

Generate Biomedicines, Inc. Research and Development Expense

Generate Biomedicines, Inc. (GENB) reported Research and Development Expense of $64.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06

  • Generate Biomedicines, Inc. research and development expense for the quarter ending 2026-06-30 was $64.33M, a 7.69% increase year-over-year.
  • Generate Biomedicines, Inc. research and development expense for the quarter ending 2026-03-31 was $57.81M, a 23.46% increase year-over-year.
  • Generate Biomedicines, Inc. research and development expense for the quarter ending 2025-06-30 was $59.73M.
  • Generate Biomedicines, Inc. research and development expense for the quarter ending 2025-03-31 was $46.83M.
Period endResearch and Development Expense 1 monthResearch and Development Expense 3 monthResearch and Development Expense 6 month
2026-06-30$64.33M
10-Q · filed 2026-08-06
$122.14M
10-Q · filed 2026-08-06
2026-03-31$57.81M
10-Q · filed 2026-05-07
2025-06-30$59.73M
10-Q · filed 2026-08-06
$106.56M
10-Q · filed 2026-08-06
2025-03-31$46.83M
10-Q · filed 2026-05-07
2021-08-31$10.00M
10-Q · filed 2026-08-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Braveheart Bio, Inc. (BRVE)United States$2.106B
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Biohaven Ltd. (BHVN)United States$1.990B-3.83
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38